Apte

Manoj Apte Joins Attivo Networks® Board of Directors

Retrieved on: 
Tuesday, June 1, 2021
Technology, Networks, Other Technology, Security, Data security, Cyberwarfare, Computer network security, Computer security, Cryptography, Cybercrime, Malware, Manoj, Nuclear Threat Initiative, Apte

Attivo Networks, the leader in lateral movement attack detection and privilege escalation prevention, today announced that Manoj Apte, former chief strategy officer Zscaler has joined the companys Board of Directors.

Key Points: 
  • Attivo Networks, the leader in lateral movement attack detection and privilege escalation prevention, today announced that Manoj Apte, former chief strategy officer Zscaler has joined the companys Board of Directors.
  • Manoj is an accomplished leader with extensive experience in product development and go-to-market strategy, said Tushar Kothari, CEO of Attivo Networks.
  • Identity is and remains the beachhead for all cybersecurity attacks, said Manoj Apte, board member of Attivo Networks.
  • To address this challenge, Attivo Networks has been thoughtfully evolving its platform to focus more broadly than its core deception area.

SEC Charges Co-Founders of San Francisco Biotech Company With $60 Million Fraud

Retrieved on: 
Thursday, March 18, 2021
Citizen science, Genetic genealogy, Microbiology, Microbiomes, uBiome, Branches of biology, Apte, Richman, Biology, Articles

"According to the complaint, Richman and Apte portrayed the company as having a strong track record of receiving health insurance reimbursement for its clinical tests, which purportedly could detect microorganisms and assist in diagnosing disease.

Key Points: 
  • "According to the complaint, Richman and Apte portrayed the company as having a strong track record of receiving health insurance reimbursement for its clinical tests, which purportedly could detect microorganisms and assist in diagnosing disease.
  • According to the complaint, Richman and Apte were each enriched by millions through selling their own uBiome shares during the fraudulent fundraising round.
  • "We allege that Richman and Apte touted uBiome as a successful and fast-growing biotech pioneer while hiding the fact that the company's purported success depended on deceit,"said Erin Schneider, Director of the SEC's San Francisco Regional Office.
  • Postal Inspection Service, Defense Criminal Investigative Service, and Department of Health and Human Services Office of Inspector General.

Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

Retrieved on: 
Monday, September 17, 2018
Indian films, Apte, BIOMED, BioMed Central, X: Past Is Present, Ophthalmology, Publishing, Cinema of India

NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that Rajendra Apte, MD, PhD has joined its Advisory Board contributing his extensive experience in the field of ophthalmology ( https://wuphysicians.wustl.edu/for-patients/featured-physicians/rajendra... ).

Key Points: 
  • NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that Rajendra Apte, MD, PhD has joined its Advisory Board contributing his extensive experience in the field of ophthalmology ( https://wuphysicians.wustl.edu/for-patients/featured-physicians/rajendra... ).
  • Dr. Apte is the Paul A. Cibis Distinguished Professor of Ophthalmologyand Visual Sciences at Washington University in St. Louis.
  • Dr. Apte is currently running a human study to investigate the correlation of GDF-15 levels with glaucoma disease severity and progression.
  • "We are honored to have Dr. Apte join our distinguished team of scientific advisors," said Denis Corin, CEO of Q BioMed.